Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term cutaneous. Found 4 abstracts

Pfister DG, Ang KK, Brizel DM, Burtness B, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE. Mucosal Melanoma of the Head and Neck. Journal of the National Comprehensive Cancer Network. 2012 Mar;10(3):320-38.   PMCID: not NIH Funded
Kim S, Eleff M, Nicolaou N. CETUXIMAB AS PRIMARY TREATMENT FOR CUTANEOUS SQUAMOUS CELL CARCINOMA TO THE NECK. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck. 2011 Feb;33(2):286-8.   PMCID: *
Miller SJ, Alam M, Andersen J, Berg D, Bichakjian CK, Bowen G, Cheney RT, Glass LF, Grekin RC, Kessinger A, Lee NY, Liegeois N, Lydiatt DD, Michalski J, Morrison WH, Nehal KS, Nelson KC, Nghiem P, Olencki T, Perlis CS, Rosenberg EW, Shaha AR, Urist MM, Wang LC, Zic JA. Basal Cell and Squamous Cell Skin Cancers. Journal of the National Comprehensive Cancer Network. 2010 Aug;8(8):836-64.   PMCID: not NIH funded
Gitelson E, Al-Saleem T, Millenson M, Lessin S, Smith MR. Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature. Leukemia & lymphoma. 2006 Sep;47(9):1902-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term cutaneous

cutaneous head NCCN Guidelines radiation-therapy NCCN Clinical Practice Guidelines actinic keratosis head and neck cancer severe comorbidities or who refused treatment with radiation lesions presentations of CBCL melanoma rituximab cancers if m(2) Maintenance therapy lymphoma intravenous infusions of 375 mg comorbidity index 1987 arlson me-journal of chronic diseases-v40-p373 topical methyl aminolevulinate metastatic melanoma pathology non-melanoma skin sunlight and cancer malignant-melanoma cancer SYSTEMIC THERAPY cutaneous site of large-cell lymphoma that developed after 3 years in m(2) once every 2-3 months Objective adjuvant radiotherapy plus cetuximab PATTERN recurrence rates neck dissection co-morbidity sinonasal melanoma FOLLICULAR-GROWTH DENDRITIC CELLS either primary CBCL or low-grade effective in treating of CBCL ELDERLY-PATIENTS contraindicated or unwanted Additional collaborative studies are remission One patient received local radiotherapy to a solitary lymphomas with relapses limited to the skin Rituximab appears to precancerous lesions locally advanced each with either extensive established We treated five patients with rituximab given as a single agent for four weekly therapy B cell 19 ongoing complete clinical remissions with a median follow-up of 17 biopsy chemotherapy remission from the low-grade CBCL present an attractive alternative when radiation therapy is CYTOTOXIC T-CELLS ANTI-CD20 MONOCLONAL-ANTIBODY skin carcinoma squamous cell carcinoma EORTC CLASSIFICATION mohs micrographic surgery postoperative radiotherapy cetuximab was given at 375 mg initiated kit mutation clinical responses occurred in all five patients Three patients have no recurrences of either grade CBCL metastatic have yet occurred Treatment was well tolerated Rituximab is safe and SCC skin TUMOR BURDEN AB Optimal treatment of cutaneous B-cell lymphoma (CBCL) is yet to be organ transplant recipients basosquamous carcinoma adjuvant therapy mucosal melanoma at age 87 years from a non-related cause after 55 years of complete photodynamic therapy NON-HODGKINS-LYMPHOMA CHOP CHEMOTHERAPY radiation therapy needed to assess the role of rituximab in various clinicopathologic Bowen's disease and 39 months post achievement of complete remission One patient died
Last updated on Friday, January 03, 2020